Lexicon Q4 net loss narrows to $15.5M; cash strengthened with $106.7M added in Feb 2026

LEXICON PHARMACEUTICALS, INC.

Q4 net loss $15.5M ($0.04/share) vs $33.8M loss ($0.09/share) in Q4 2024; full-year loss $50.3M.
Q4 revenue $5.5M including $4.3M licensing from Novo Nordisk and $1.1M INPEFA sales.
Cash, investments, restricted cash $125.2M at Dec 31, 2025; $96.7M capital raise + $10M Novo milestone in Feb 2026.
SONATA-HCM enrollment >50% of 500 patients; on track for mid-2026 completion and Q1 2027 topline.
NDA resubmission for ZYNQUISTA in T1D on track for 2026; positive End-of-Phase 2 meeting for pilavapadin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.